ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

934
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Insights

The Future of Global Drug Regulation

Executive Summary Drug regulation is entering a period of significant transformation. For decades, pharmaceutical regulation has relied on established scientific standards,...
Insights

Why Pharmaceutical Companies Need AI Factories

Executive Summary Artificial intelligence is moving from experimentation to infrastructure. Pharmaceutical companies have spent the past several years testing AI across...
Regulatory

Phase 3 of Merck and Moderna’s customized cancer vaccine lowers recurrence, paving the way for approval

Key Trial Breakthrough in Skin Cancer The personalized mRNA cancer vaccine developed by Merck & Co. and Moderna has proven...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Manufacturing

Aura Biosciences Refocuses on Ocular Oncology Programs and Cuts Workforce by 20%

Aura Biosciences is restructuring its operations under recently appointed...
Editorial Team -
Manufacturing

Ensoma Restructures Operations to Focus on EN-374 for X-Linked Chronic Granulomatous Disease

Boston-based biotechnology company Ensoma has carried out another organizational...
Editorial Team -
Manufacturing

Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertising Claims

Novo Nordisk has filed a lawsuit against Eli Lilly...
Editorial Team -
Manufacturing

Edgewise Reports Phase 2 CIRRUS-HCM Results for EDG-7500 Ahead of Planned Phase 3 Development

Edgewise Therapeutics has reported top-line results from Part D...
Editorial Team -